Avidity Announces 2021 Pipeline Updates For DM1, FSHD, DMD
Free-Photos / Pixabay

Avidity Announces 2021 Pipeline Updates For DM1, FSHD, DMD

In early January 2021, biopharmaceutical company Avidity Biosciences ("Avidity") announced updates from its 2021 pipeline. Currently, Avidity is working to create a line of Antibody Oligonucleotide Conjugates (AOCs), therapeutic options…

Continue Reading Avidity Announces 2021 Pipeline Updates For DM1, FSHD, DMD

A New Method of Delivering Drugs Through the Blood-Brain Barrier To Treat Neurological Disorders

Over the past decade, scientists have made many life-saving advances in all areas of medicine. They have created molecular agents to target neurodegenerative diseases. But they were stopped right there…

Continue Reading A New Method of Delivering Drugs Through the Blood-Brain Barrier To Treat Neurological Disorders